Reuters reports that pharmaceutical companies, including Pfizer (NYSE:PFE), GlaxoSmithKline (NYSE:GSK) and Sanofi (NASDAQ:SNY), are planning to raise prices on more than 200 medicines in the U.S. tomorrow.
The price hikes are expected to be relatively modest, almost all below 10% and half between 4 – 6%.
Pfizer intends to boost prices on more than 50 drugs, including breast cancer med Ibrance (palbociclib) and arthritis/UC med Xeljanz (tofacitinib). A spokesperson stated that the average increase will be 5.6%.
GSK plans to raise prices on more than 30 medicines by 1 – 5%.
Sanofi will follow suit on ~10 drugs by 1 – 5%.
According to healthcare research shop 3 Axis Advisors, Teva Pharmaceutical Industries (NYSE:TEVA) raised prices on more than 15 drugs by more than 6%.
Viveve Medical to continue Nasdaq listing; shares up 6% premarket
Nano cap Viveve Medical (NASDAQ:VIVE) is up 6% premarket on modest volume in response to its announcement that it has regained compliance with listing requirements and shares will continue to trade on the Nasdaq Capital Market.
Oragenics files for $50M equity offering
Oragenics (NYSEMKT:OGEN) has filed a prospectus for a $50M offering of common stock, warrants and/or units. Shares down 2% after hours.
Pot stocks poised to end year on high note
Cannabis stocks are enjoying end-of-the-year buying today, giving battered longs hope for a better 2020.
